drugset / Trial / NCT01310166

Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis

NCT01310166

Phase 4 Completed 447 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to investigate which changes in immunological biomarkers under treatment with fingolimod in patients with relapsing-remitting multiple sclerosis can be detected.

Timeline

Start
2011-02
Primary completion
2012-07
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Fingolimod Small molecule 0.5 mg